Abstract Library

#4665 Prognostic value of systemic inflammatory parameters in neuroendocrine tumour patients treated with peptide receptor radionuclide therapy – Preliminary results

Introduction: PRRT (177Lu-Dotatate) is a therapeutic option for advanced NETs (neuroendocrine tumours). Systemic inflammatory parameters, such as NLR, PLR, SII, and other ratios derived from complete blood counts, are considered prognostic markers in NETs and other malignancies.

Conference:

Presenting Author: Maciejewski A

Authors: Maciejewski A, Komarnicki P, Musiałkiewicz J, Gut P, Ruchała M,

Keywords: neuroendocrine tumour, PRRT, systemic inflammatory parameter, PLR, prognostic biomarker,

#4549 Alpha-Fetoprotein as a valuable biomarker in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are a rare group of tumours that pose a significant diagnostic, therapeutic, and prognostic challenge. This complexity arises from the diversity and heterogeneity of these neoplasms, as well as from the limitations of commonly used biomarkers in clinical practice. Alpha-fetoprotein (AFP) is a fetal protein widely used primarily for congenital defects in prenatal diagnostics and in certain malignancies in adults.

Conference:

Presenting Author:

Authors: Musiałkiewicz J, Gut P, Komarnicki P, Maciejewski A, Ruchała M,

Keywords: alpha-fetoprotein, biomarker, neuroendocrine tumour,

#4528 Serum visfatin concentration in metastatic pancreatic and midgut NETs: An exploratory study

Introduction: Neuroendocrine tumours (NETs) are commonly diagnosed at advanced stages due to their diverse and often asymptomatic clinical presentation. Visfatin, an adipocytokine involved in regulating cellular energy homeostasis, inflammation, and tumorigenesis, has been investigated as a potential biomarker in several neoplasms. However, its role in NETs remains unexplored.

Conference:

Presenting Author:

Authors: Komarnicki P, Maciejewski A, Musiałkiewicz J, Mastorakos G, Gut P,

Keywords: visfatin, biomarker, nicotinamide phosphoribosyltransferase, NAMPT, PBEF, eNAMPT,

#4442 Prevalence of second primary malignancies in patients with neuroendocrine tumours – Experience from a tertiary reference centre

Introduction: Neuroendocrine tumours (NETs) constitute a diverse group of tumours. NETs are often diagnosed late, due to nonspecific symptoms. Second Primary Malignancies (SPMs) have been reported in up to 25% of NETs and their incidence has been described as negative predictor of OS.

Conference:

Presenting Author:

Authors: Komarnicki P, Woliński K, Maciejewski A, Musiałkiewicz J, Gut P,

Keywords: neuroendocrine neoplasm, neuroendocrine tumour, second primary malignancy, secondary malignancy, second primary neoplasm,

#4214 Splenic metastases in the course of neuroendocrine tumors – Are they really that uncommon?

Introduction: Splenic metastases are described as exceptional in the literature. Their frequency is low regardless of the type of neoplasm. In the course of neuroendocrine tumors (NETs), spleen involvement seems infrequent too. There is only a limited number of case reports of such presentation.

Conference:

Presenting Author:

Authors: Maciejewski A, Komarnicki P, Wietrzyk D, Musiałkiewicz J, Woliński K,

Keywords: NETs, metastases, spleen, clinical course,